Quanta is developing allosteric small molecules to target previously undruggable KRAS mutations, specifically KRASG12D and KRASG12V, in cancers such as pancreatic, colorectal, and lung. Their proprietary Second Harmonic Generation platform enables the discovery of these inhibitors, addressing the significant patient population that remains untreated by existing KRAS therapies.
Funding
$142.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
KRAS mutations drive nearly one-quarter of all cancers, but effective therapies are limited, particularly for mutations beyond KRASG12C, leaving a significant patient population with unmet needs in cancers like pancreatic, colorectal, lung, and endometrial. These cancers often rely on KRASG12D and KRASG12V mutations, which have historically been difficult to target.
Solution
Quanta Therapeutics is developing allosteric small molecule inhibitors targeting previously undruggable KRAS mutations, such as KRASG12D and KRASG12V, to address a broad spectrum of RAS-driven cancers. Their approach focuses on modulating RAS signaling at the cell membrane, utilizing deep biologic insight, unique protein conformation detection technology via their Second Harmonic Generation (SHG) platform, and sophisticated medicinal chemistry. This enables the discovery of chemically distinct KRAS inhibitor programs with differentiated mechanisms of action. The pipeline includes orally bioavailable, CNS-penetrant KRAS inhibitors designed to expand the scope of treatable KRAS-mutated cancers.
Target Audience
The primary target audience includes patients with RAS-driven cancers, particularly those with KRASG12D and KRASG12V mutations in cancers such as pancreatic, colorectal, lung, and endometrial, as well as the physicians who treat them.
Features
- Orally bioavailable, CNS-penetrant small molecule inhibitors
- Programs targeting KRASG12D, KRASG12V, and multi-KRAS mutations
- Lead assets QTX3034 (G12D-preferring multi-KRAS), QTX3046 (G12D-selective), and QTX3544 (G12V-preferring multi-KRAS)
- QTX3034 and QTX3046 are currently being evaluated in Phase 1 clinical trials, with QTX3544 also in Phase 1 dose escalation
- Second Harmonic Generation (SHG) platform for high-throughput, conformation-sensitive drug discovery
- Allosteric modulation of signaling complexes in the mitogen-activated protein kinase (MAPK) pathway
- Programs with potential as both monotherapies and synthetic lethal combination partners